Thrombotic microangiopathy syndromes.
Zakarija
Anaadriana
A
Division of Hematology/Oncology, Northwestern University, 676 N. St. Clair, Suite 850, Chicago, IL 60611, USA. z-anaadriana@northwestern.edu
D051722:ADAM Proteins / Q000172:deficiency / Q000276:immunology / Q000502:physiology; D000071120:ADAMTS13 Protein; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001323:Autoantibodies / Q000276:immunology; D000068258:Bevacizumab; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy; D010951:Plasma Exchange; D011183:Postoperative Complications / Q000209:etiology; D057049:Thrombotic Microangiopathies / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001323:Autoantibodies; D007166:Immunosuppressive Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human